Suppr超能文献

心力衰竭和慢性肾脏病患者肾功能与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂剂量的长期变化

Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.

作者信息

Fröhlich Hanna, Nelges Christoph, Täger Tobias, Schwenger Vedat, Cebola Rita, Schnorbach Johannes, Goode Kevin M, Kazmi Syed, Katus Hugo A, Cleland John G F, Clark Andrew L, Frankenstein Lutz

机构信息

Department of Cardiology, University of Heidelberg, Heidelberg, Germany.

Department of Nephrology, University of Heidelberg, Heidelberg, Germany.

出版信息

Am Heart J. 2016 Aug;178:28-36. doi: 10.1016/j.ahj.2016.03.024. Epub 2016 Apr 30.

Abstract

BACKGROUND

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have become cornerstones of therapy for chronic heart failure (CHF). Guidelines advise high target doses for ACEIs/ARBs, but fear of worsening renal function may limit dose titration in patients with concomitant chronic kidney disease (CKD).

METHODS

In this retrospective observational study, we identified 722 consecutive patients with systolic CHF, stable CKD stage III/IV (estimated glomerular filtration rate [eGFR] 15-60 mL min(-1) 1.73 m(-2)) and chronic ACEI/ARB treatment from the outpatient heart failure clinics at the Universities of Hull, UK, and Heidelberg, Germany. Change of renal function, worsening CHF, and hyperkalemia at 12-month follow-up were analyzed as a function of both baseline ACEI/ARB dose and dose change from baseline.

RESULTS

ΔeGFR was not related to baseline dose of ACEI/ARB (P = .58), or to relative (P = .18) or absolute change of ACEI/ARB dose (P = .21) during follow-up. Expressing change of renal function as a categorical variable (improved/stable/decreased) as well as subgroup analyses with respect to age, sex, New York Heart Association functional class, left ventricular ejection fraction, diabetes, concomitant aldosterone antagonists, CKD stage, hypertension, ACEI vs ARB, and congestion status yielded similar results. There was no association of dose/dose change with incidence of either worsening CHF or hyperkalemia.

CONCLUSIONS

In patients with systolic CHF and stable CKD stage III/IV, neither continuation of high doses of ACEI/ARB nor up-titration was related to adverse changes in longer-term renal function. Conversely, down-titration was not associated with improvement in eGFR. Use of high doses of ACEI/ARB and their up-titration in patients with CHF and CKD III/IV may be appropriate provided that the patient is adequately monitored.

摘要

背景

血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)已成为慢性心力衰竭(CHF)治疗的基石。指南建议使用ACEI/ARB的高目标剂量,但对于合并慢性肾脏病(CKD)的患者,担心肾功能恶化可能会限制剂量滴定。

方法

在这项回顾性观察性研究中,我们从英国赫尔大学和德国海德堡大学的门诊心力衰竭诊所中,确定了722例连续的收缩性CHF患者,这些患者处于稳定的CKD III/IV期(估计肾小球滤过率[eGFR]为15 - 60 mL·min⁻¹·1.73 m⁻²)且正在接受慢性ACEI/ARB治疗。在12个月的随访中,分析肾功能变化、CHF恶化和高钾血症与基线ACEI/ARB剂量以及相对于基线的剂量变化之间的关系。

结果

ΔeGFR与ACEI/ARB的基线剂量无关(P = 0.58),也与随访期间ACEI/ARB剂量的相对变化(P = 0.18)或绝对变化(P = 0.21)无关。将肾功能变化表示为分类变量(改善/稳定/下降),以及针对年龄、性别、纽约心脏协会功能分级、左心室射血分数、糖尿病、同时使用醛固酮拮抗剂、CKD分期、高血压、ACEI与ARB以及充血状态进行亚组分析,均得出相似结果。剂量/剂量变化与CHF恶化或高钾血症的发生率均无关联。

结论

对于收缩性CHF且处于稳定的CKD III/IV期的患者,继续使用高剂量ACEI/ARB或增加剂量均与长期肾功能的不良变化无关。相反,降低剂量与eGFR的改善无关。只要对患者进行充分监测,在CHF和CKD III/IV期患者中使用高剂量ACEI/ARB及其增加剂量可能是合适的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验